ASAM eLearning
Catalog Advanced Search
-
Impact of Nicotine and Other Stimulants on Sleep in Young Adults (1 CME)
Contains 4 Component(s), Includes CreditsEarn 1 AMA PRA Category 1 Credit(s)™ while learning about the impact of stimulants on sleep in young adults from The Journal of Addiction Medicine 2019.
Earn 1 AMA PRA Category 1 Credit(s)™ while learning about the impact of stimulants on sleep in young adults in this journal article from The Journal of Addiction Medicine 2019. Michael D. Stein, MD, Celeste M. Caviness, PhD and Bradley J. Anderson, PhD
Learning objectives:
1.) Explore the relationship of commonly used stimulant substances to poor sleep in quality in young adults
2.) Assess the varying impact of different stimulants on sleep
-
Recovery Goals and Long-term Treatment Preference in Persons Who Engage in Nonmedical Opioid Use (1 CME)
Contains 4 Component(s), Includes CreditsEarn 1 AMA PRA Category 1 Credit(s)™ while learning about recovery and treatment with nonmedical opioid use from The Journal of Addiction Medicine 2019.
Earn 1 AMA PRA Category 1 Credit(s)™ while learning about the recovery and treatment with nonmedical opioid use in this journal article from The Journal of Addiction Medicine 2019. Andrew S. Huhn, PhD, MBA, Kaitlyn R. Hay, MS, David Andrew Tompkins, MD, MHS, Kelley E. Dunn, PhD
Learning objectives:
1.) Identify recovery goals and treatment preferences to maximize treatment initiation and retention
2.) Explain the proportion of out of treatment individuals with non-medical opioid use that have abstinent and non-abstinent recovery goals
3.) Understand how patients can be matched to treatments, which can help promote early treatment satisfaction and retention
-
Opioid and Cannabis Co-Use among Adults with Chronic Pain: Relations to Substance Misuse, Mental Health, and Pain Experience(1 CME)
Contains 4 Component(s), Includes CreditsEarn 1 AMA PRA Category 1 Credit(s)™ while learning about opioid and cannabis co-use among adults with chronic pain The Journal of Addiction Medicine 2019.
Earn 1 AMA PRA Category 1 Credit(s)™ while learning about learning about opioid and cannabis co-use among adults with chronic pain in this journal article from The Journal of Addiction Medicine 2019. Andrew S. Huhn, PhD, MBA, Kaitlyn R. Hay, MS, David Andrew Tompkins, MD, MHS, Kelley E. Dunn, PhD
Learning objectives:
1.) Identify how the co-use of substances is generally associated with poorer outcomes than single substance use
2.) Understand how opioid and cannabis co-use is associated with higher anxiety and depression symptoms
-
Webinar: The ASAM Criteria Copyright and Permissions Process for States
Contains 1 Component(s)In this free webinar, learn about the ASAM Criteria copyright and permissions process for states.
Webinar Overview
In Spring 2019, The ASAM Criteria copyright and permissions process was updated to include agreements to enable public entities, providers, and other stakeholders to reference their use of The ASAM Criteria. The changes are part of a range of programs designed to support effective implementation of The ASAM Criteria and protect ASAM’s intellectual property from misuse. These programs include an ASAM Level of Care certification program delivered by CARF, a robust training program on The ASAM Criteria, and ongoing enhancements to the ASAM CONTINUUM software – a clinical decision support tool used to assist in treatment planning for individuals with addiction. All of these initiatives have the end goals of protecting patients and preserving the credibility of providers accurately implementing the evidence-based standards found in The ASAM Criteria.
Margaret A.E. Jarvis
MD, DFASAM
Margaret Jarvis finished her medical school, psychiatry residency and Addiction Medicine Fellowship at the Medical College of Virginia in Richmond. She is board certified and recertified in psychiatry with the CAQ in Addiction Psychiatry. She was ASAM certified (now ABAM certified). She has been a member of ASAM since the early 90’s and became a Fellow of the Society in 2003. She has served on the Board of Directors for one term and currently is the co-chair of the Ruth Fox Planning; and a member of the Finance Committee and the Constitution and Bylaws Committee. She has also worked on Examination Committee for ASAM and now ABAM since 2000.
Dr. Jarvis is the Medical Director at Marworth, in Waverly, PA, which is the residential addiction treatment center for the Geisinger Health System. She has been in this position since 1999. She is also Clinical Assistant Professor of Psychiatry at the Penn State University College of Medicine in Hershey, PA.
Dr. Jarvis is a member of the Society for the Advancement of Sexual Health, a professional organization of therapists who treat sexual addiction, and served on that board of directors from 2001-2006, as president from 2004-2006. She received the Merit award from SASH in 2011. Dr. Jarvis currently serves as the Treasurer of the Board of Marley’s Mission, a non-profit that provides equine-assisted psychotherapy to abused children in the Scranton, PA area.
-
Webinar: The ASAM Criteria Copyright and Permissions Process for Providers
Contains 1 Component(s)In this free webinar, learn about the ASAM Criteria copyright and permissions process for providers.
Webinar Overview
In Spring 2019, The ASAM Criteria copyright and permissions process was updated to include agreements to enable public entities, providers, and other stakeholders to reference their use of The ASAM Criteria. The changes are part of a range of programs designed to support effective implementation of The ASAM Criteria and protect ASAM’s intellectual property from misuse. These programs include an ASAM Level of Care certification program delivered by CARF, a robust training program on The ASAM Criteria, and ongoing enhancements to the ASAM CONTINUUM software – a clinical decision support tool used to assist in treatment planning for individuals with addiction. All of these initiatives have the end goals of protecting patients and preserving the credibility of providers accurately implementing the evidence-based standards found in The ASAM Criteria.
Margaret A.E. Jarvis
MD, DFASAM
Margaret Jarvis finished her medical school, psychiatry residency and Addiction Medicine Fellowship at the Medical College of Virginia in Richmond. She is board certified and recertified in psychiatry with the CAQ in Addiction Psychiatry. She was ASAM certified (now ABAM certified). She has been a member of ASAM since the early 90’s and became a Fellow of the Society in 2003. She has served on the Board of Directors for one term and currently is the co-chair of the Ruth Fox Planning; and a member of the Finance Committee and the Constitution and Bylaws Committee. She has also worked on Examination Committee for ASAM and now ABAM since 2000.
Dr. Jarvis is the Medical Director at Marworth, in Waverly, PA, which is the residential addiction treatment center for the Geisinger Health System. She has been in this position since 1999. She is also Clinical Assistant Professor of Psychiatry at the Penn State University College of Medicine in Hershey, PA.
Dr. Jarvis is a member of the Society for the Advancement of Sexual Health, a professional organization of therapists who treat sexual addiction, and served on that board of directors from 2001-2006, as president from 2004-2006. She received the Merit award from SASH in 2011. Dr. Jarvis currently serves as the Treasurer of the Board of Marley’s Mission, a non-profit that provides equine-assisted psychotherapy to abused children in the Scranton, PA area.
-
Webinar: What is ASAM Level of Care Certification?
Contains 1 Component(s)In this free webinar, learn about the ASAM Level of Care certification and the pilot process that was used to ensure its validity.
Webinar Overview
This webinar provides an overview of ASAM Level of Care certification and the pilot process that was used to ensure its validity. ASAM Level of Care certification, delivered in partnership with CARF International, is the first program of its kind to independently assess and verify treatment programs’ ability to deliver services consistent with the levels of care described in The ASAM Criteria. It will initially cover adult residential programs at Levels 3.1, 3.5, and 3.7 of The ASAM Criteria. The certification demonstrates a program’s capacity to deliver a specific level of care, thereby differentiating between the many levels of care available for addiction treatment.
Paul H. Earley
MD, DFASAM
Dr. Earley has worked in Addiction Medicine for over 30 years. He treats all types of addictive disorders and specializes in the assessment, treatment and management of health care professionals. As a therapist, he works with patients already in recovery, providing long term therapy for those who suffer from this disease. His professional expertise extends to advocacy for professionals before agencies and licensing boards.
Dr. Earley is a dynamic speaker and educator; he speaks and trains on topics of addiction, its treatment and addiction among health care professionals. In addition, he trains therapists about the neurobiological basis of psychotherapy. In his travels, he has provided training in the United States, Canada, the United Kingdom, Italy, Iceland and Switzerland.
He is the author of two books and several research articles on addiction and its treatment. His most recent book, RecoveryMind Training is an innovative and comprehensive process designed to reengineer addiction treatment. He is a contributing author to the American Society of Addiction Medicine (ASAM) Textbook: Principles of Addiction Medicine, as author of the chapter: Physician Health Programs and Addiction among Physicians. He is a contributing author to the ASAM Criteria. His work was featured in the documentary series on addiction entitled Close to Home by Bill Moyers.
Currently, Dr. Earley is the Medical Director of the Georgia Professionals Health Program, Inc., the Physicians Health Program (PHP) for the state of Georgia and the President-elect of the Federation of State Physician Health Programs (FSPHP). Dr. Earley is the current president-elect of the American Society of Addiction Medicine (ASAM). He is a Distinguished Fellow of ASAM and has served on the board of ASAM for over 14 years in several capacities.
Michael W. Johnson
MA, CAP
Michael joined CARF as managing director of the Behavioral Health accreditation area in 2013. A certified addictions professional, Michael has more than 30 years of experience as a clinician, manager, and executive working in mental health, substance abuse, and intellectual disabilities. He was a CARF surveyor for 16 years and holds a master's degree in communications from the University of Central Florida.
-
ASAM 50th Annual Conference - Innovations in Addiction Medicine and Science - 2019 (85 CME)
Contains 63 Product(s)Earn a maximum of 85 AMA PRA Category 1™ credits while learning about the latest innovations in Addiction Medicine and Science from these on-demand conference recordings from the nation’s premiere conference on the latest science, research, best practices and innovations in addiction medicine.
Overview
The ASAM Annual Conference is the nation’s premiere event showcasing best practices and the latest science, research, and innovations in addiction medicine. View over 60 high-quality educational sessions on a variety of topics to address your educational needs!
Learning Objectives
At the conclusion of this activity, participants should be able to:
- Identify and describe the new developments affecting the science, policy, and clinical practice of addiction medicine.
- Compare presented clinical guidelines/best practices with the participant's current practice and identify strengths or gaps.
- Analyze new research and science to develop practical applications for treatment or further research.
- Explain recent or upcoming policy changes and identify implications or areas for provider involvement.
ACCME Accreditation Statement
The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
AMA Credit Designation Statement
The American Society of Addiction Medicine designates this enduring material for a maximum of 85 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ABPM Maintenance of Certification (MOC)
The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 85 LLSA credits towards ABPM MOC Part II requirements.
ABAM Transitional Maintenance of Certification (tMOC)
This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Transitional Maintenance of Certification Program (tMOC) can apply a maximum of 85 AMA PRA Category 1 Credit(s)™ for completing this course.
ABIM Maintenance of Certification (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn 85 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Who Should Attend
Healthcare professionals dedicated to increasing access and improving the quality of addiction treatment and care, including:
- Physicians and Clinicians
- Researchers and Academics
- Students and Retirees
- Counselors and Policymakers
-
Overdose Fatality Reviews: A Data-Driven Collaboration (1.5 CME)
Contains 4 Component(s), Includes CreditsEarn 1.5 AMA PRA Category 1 Credit(s)™ while learning about the structure and process of overdose fatality reviews. from this conference recording from The ASAM 50th Annual Conference (2019).
(1.5 CME) In this conference recording from the 2019 Annual Conference, you will learn:
Overdose fatality reviews allow communities to examine and understand the circumstances surrounding fatal drug overdoses. Review teams can uncover the individual and population factors and characteristics of potential overdose victims. Knowing the who, what, when, where, and how of fatal overdoses provides a better sense of the strategies and coordination needed to prevent future overdoses and results in the better allocation of overdose prevention resources and services. This session will provide an overview of overdose fatality review and highlight successes and challenges in the field from local, state and tribal perspectives. Funding and training and technical assistance opportunities through Bureau of Justice Assistance will be highlighted. There will be a panel of four individuals and the session will include funding and training opportunities from the Bureau of Justice Assistance, an overview of the structure and process of an overdose fatality review, a state level view of the OFR model and features in Wisconsin, and a local level view in Prince George County Maryland. Tara L. Kunkel
MSW
Tara Kunkel is presently on detail to the Department of Justice, Bureau of Justice Assistance through an interagency agreement serving as a Senior Drug Policy Advisor. Ms. Kunkel oversees BJA’s prescription drug monitoring program as well as the Comprehensive Opioid Abuse Program. Ms. Kunkel graduated from Virginia Commonwealth University with a Masters in Social Work and received her BA in Psychology from the University of Virginia. ACCME Accreditation Statement
The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
AMA Credit Designation Statement
The American Society of Addiction Medicine designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ABPM Maintenance of Certification (MOC)
The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 1.5 LLSA credits towards ABPM MOC Part II requirements.
ABAM Transitional Maintenance of Certification (tMOC)
This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Transitional Maintenance of Certification Program (tMOC) can apply a maximum of 1.5 AMA PRA Category 1 Credit(s)™ for completing this course.
ABIM Maintenance of Certification (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn 1.5 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
-
Up in Smoke: Igniting Recovery from Tobacco and e-Cigarettes (1.5 CME)
Contains 4 Component(s), Includes CreditsEarn 1.5 PRA Category 1 Credit(s)™ while learning how to improve nicotine and tobacco research from this conference recording from The ASAM 50th Annual Conference (2019).
1.5 CME In this conference recording from the 2019 Annual Conference, you will learn that:
Historically, substance use disorder treatment centers have only offered limited-to-no treatment for tobacco dependence during their programs. Over the last 30 years, significant gains have been made in behavioral management for tobacco dependence, FDA approval of 7 medications, development of outpatient and inpatient treatment protocols, and the establishment of tobacco-free hospitals and behavioral treatment centers. In addition, tobacco price elasticity, increased public health knowledge of risks, restrictions in tobacco marketing, and clean, indoor-air laws have resulted in lower tobacco consumption in the general population. However, these gains have not had enough impact to lower the rates of tobacco-related chronic health diseases in individuals with substance use disorders. Tobacco use is the number one cause of death for people with alcoholism1 . Furthermore, there are potential threats to the advances already made, including the rapid acceptance of electronic nicotine delivery systems (ENDS) within the last 10 years and the decriminalization and/or legalization of recreational or medical of cannabis use in 30 states over the past two decades. The increasing awareness of tobacco-related, chronic disorders amongst both the public and medical professionals presents an opportune climate for improving the screening and treatment of tobacco dependence in patients receiving treatment for other addictions. Four potential opportunities include:
1) Dissemination of an increasing number of novel, evidenced-based protocols specifically for individuals with tobacco and co-occurring substance use disorders; 2) Recognition by medical and behavioral health providers of patient satisfaction and improved outcomes when tobacco is addressed during addiction therapy; 3) Identification, training and collaboration of addiction specialists to advance this concept; and 4) Awareness of the potential use of ENDS to intentionally deliver other drugs of abuse and need for education of patients and staff about impact of ENDS products on long-term recovery. This workshop will offer best practices of current evidence-based protocols and provide tools for creating effective treatment options that can be applied in a variety of settings. The participants will engage in small group, interactive exercises that will develop action plans for addressing tobacco-use disorders within their own treatment settings and on a national level. Outline: Review important historical milestones in efforts to treat tobacco dependence in addiction settings Discuss potential threats for gains already made in the treatment of tobacco dependence over two decades Discuss potential opportunities and challenges to improve the treatment of tobacco dependence for recovering populations Each participant will be empowered to develop a personalized Strengths, Weakness, Opportunities and Threats (SWOT) analysis of their program during the workshop.Learning Objectives:
Upon completion, participant will be able to:
Develop 3 novel and effective strategies for improving nicotine and tobacco treatment research, reimbursement, and service delivery.
Lori D. Karan
MD, DFASAM, FACP
Lori Karan, MD, DFASAM, FACP is Professor of Internal Medicine and Preventive Medicine and Director of the Addiction Medicine Fellowship at the Loma Linda University Medical School. She works in the Substance Treatment and Recovery (STAR) program of the Loma Linda VA Healthcare System (LLVAHCS). During her internal medicine training, Dr. Karan repeatedly treated patients for the consequences of tobacco use. She recognized that nicotine and tobacco use were often ignored during the treatment of other substance use disorders and that tobacco was the number one cause of death in recovering persons.
Dr. Karan guest-edited a seminal issue of the Journal of Substance Abuse Treatment entitled “Towards a Broader View of Recovery.” These experiences set the foundation for Dr. Karan’s longstanding interest in in the similarities and differences between nicotine and other addictive drugs. Dr. Karan advocated for tobacco control, including befriending the Phillip Morris whistleblower scientists and putting forth stockholder’s proposals during annual meetings of Phillip Morris, and RJ Reynolds. She received a NIDA Scientist Development Award where she researched the discriminative stimulus effects and neuroendocrine basis for the subjective effect of nicotine.
Dr. Karan and John Rosecrans PhD co-chaired nine annual ASAM Nicotine Research Round tables and from this excitement originated the Society for Research on Nicotine and Tobacco. More recently Dr. Karan and Dr. Susan Blank authored the Nicotine and Tobacco chapter of the ASAM Criteria where they advocated for increased intensity of treatment for persons who had severe nicotine/tobacco use disorders, medical, and/or psychiatric co-morbidity. Dr. Karan was recruited to LLVAHCS by Dr. Linda Ferry, originator of Zyban. Dr. Ferry and Dr. Karan continue to develop effective treatments for nicotine and tobacco use, especially in patients who have other substance use disorders. 1 Hurt RD et al. “Mortality following inpatient addictions treatment.” JAMA 1996 Apr 10; 275(14):1097-1103.Laura Martin
MD, FASAM
Laura F. Martin, M.D. is an Associate Professor of Psychiatry at the University of Colorado School of Medicine. She is a board certified psychiatrist and addiction medicine specialist. She has been recognized as a member of the American College of Psychiatrists, a Fellow of the American Society of Addiction Medicine, and a Distinguished Fellow of the American Psychiatric Association. Her professional roles include serving as the Medical Director of the Center for Dependence, Addiction and Rehabilitation (CeDAR), Program Director of the Addiction Medicine Fellowship at the University of Colorado School of Medicine, and as President of the Colorado Society of Addiction Medicine. She regularly works with individuals with both substance use disorders and other behavioral health disorders to improve their physical and mental health and has published peer reviewed research and clinical reviews regarding this work.
Linda Hyder Ferry
MD, MPH
Chad D. Morris
PhD
Chad Morris, Ph.D. is a Professor of Psychiatry at the University of Colorado- School of Medicine, and Director of the Behavioral Health & Wellness Program. He is the principal investigator of many projects and studies exploring the effectiveness of organizational, psychosocial, and pharmacologic wellness and tobacco cessation strategies. As the Vice President of Spark Inspiration, Dr. Morris also offers corporate wellness solutions. He has worked with over 40 states to foster sustainable whole health and tobacco control initiatives for priority populations including persons with mental illnesses, addictions, and justice involved individuals. ACCME Accreditation Statement
The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
AMA Credit Designation Statement
The American Society of Addiction Medicine designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ABPM Maintenance of Certification (MOC)
The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 1.5 LLSA credits towards ABPM MOC Part II requirements.
ABAM Transitional Maintenance of Certification (tMOC)
This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Transitional Maintenance of Certification Program (tMOC) can apply a maximum of 1.5 AMA PRA Category 1 Credit(s)™ for completing this course.
ABIM Maintenance of Certification (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn 1.5 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
-
Expanding Access to Buprenorphine for Justice-Involved Individuals via Mobile Treatment (1.5 CME)
Contains 4 Component(s), Includes CreditsEarn 1.5 AMA PRA Category 1 Credit(s)™ while learning how to expand access to MAT for justice-involved individuals from this conference recording from The ASAM 50th Annual Conference (2019).
(1.5 CME) In this conference recording from the 2019 Annual Conference, you will learn that:
Opioid use disorder (OUD) is highly prevalent among justice-involved individuals. Despite evidence that increasing access to medications for addiction treatment (MAT) decreases fatal overdoses after release from prison and jail, many barriers to expanding treatment for this population remain. Most interventions to date have focused on expanding access to MAT inside the criminal justice system, which can work well for those serving longer sentences in prisons, but the high turnover in jails and pre-trial detention centers is not always amenable to starting MAT inside jail.
In this interactive panel discussion, we will describe the development of Project Connections to Re-Entry (PCARE), a novel treatment model to expand access to buprenorphine for justice-involved individuals. Started in November 2017, PCARE is part of a network of low-threshold buprenorphine treatment site run by Behavioral Health Leadership Institute (BHLI). PCARE provides access to low threshold MAT through a mobile van parked directly outside the Baltimore City Jail in partnership with Maryland Department of Public Safety and Correctional Services. Patients are referred by jail staff or can walk in from the street. The clinical team includes an experienced primary care physician who prescribes buprenorphine, a nurse, and a peer recovery coach. Once stabilized, patients are transitioned to longer-term treatment programs or primary care for buprenorphine maintenance.
Between November 2017 and July 2018, 249 people approached the van, 127 of whom began treatment with buprenorphine-naloxone. The majority of patients (94.4%) had previous criminal justice involvement, were unemployed (72.4%) and were living with family or friends (41.7%). Of those who began treatment, 67.7% returned for a second visit or more, and 29% percent were still involved in treatment after 30 days. This focus session will begin with brief overview of current literature regarding access to MAT in criminal justice settings. The interdisciplinary panel, composed of the program director (a lawyer) and physicians, will then describe the process of developing this program, client characteristics and initial outcomes, and implications for expansion to other treatment settings.
The panel will discuss successes and challenges in partnering with detention center staff and engaging vulnerable populations in care. After the panel discussion, the group will break into small groups to discuss ways of expanding access to buprenorphine in their own settings. There will be time at end for Q+A. Proposed Timeline (in minutes): 0:00 �" 0:10 Brief review of literature related to MAT in criminal justice setting and mobile treatment models 0:10 �" 0:55 Panel discussion of PCARE low-threshold buprenorphine model 0:55 �" 1:10 Breakout into small groups to discuss expanding treatment in their own settings 1:10 �" 1:30 Questions and Answers/Session EvaluationLearning Objectives:
1.) Describe current literature on MAT for justice-involved populations.
2.) Describe a model of low threshold buprenorphine treatment for justice-involved individuals
3.) Identify ways to partner with criminal-justice settings and expand access to MAT for justice-involved individuals in their own geographic area
Megan Buresh
MD
Dr. Megan Buresh is an Assistant Professor of Medicine and Epidemiology at the Johns Hopkins University School of Medicine. She is board certified in internal medicine and addiction medicine and certified as AAHIVM HIV Specialist. She received a Bachelor of Arts in Biochemical Sciences from Harvard University (magna cum laude with highest honors in field), completed medical school at Johns Hopkins University School of Medicine and residency at Brigham and Women’s Hospital. She is the Secretary of the Maryland-DC ASAM Chapter. She is medical director of the Johns Hopkins Bayview Inpatient Addiction Consult Service. She also provides integrated buprenorphine treatment as part of her outpatient primary care practice. She is lead physician for BHLI PCARE, a mobile buprenorphine clinic for patients being released from Baltimore City Jail. Her research interests include public health and addiction, developing and evaluating models to expand office-based opioid treatment, and improving linkages between clinical addiction treatment and community organizations. She is a co-investigator with the ALIVE study at the Johns Hopkins Bloomberg School of Public Health, where she is studying risk factors for opiate overdose and access to naloxone among persons who inject drugs. ACCME Accreditation Statement
The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
AMA Credit Designation Statement
The American Society of Addiction Medicine designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ABPM Maintenance of Certification (MOC)
The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 1.5 LLSA credits towards ABPM MOC Part II requirements.
ABAM Transitional Maintenance of Certification (tMOC)
This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Transitional Maintenance of Certification Program (tMOC) can apply a maximum of 1.5 AMA PRA Category 1 Credit(s)™ for completing this course.
ABIM Maintenance of Certification (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn 1.5 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
